Introduction {#sec1}
============

Acetogenins, an abundant, structurally diverse group of natural compounds, are isolated from the Annonaceae plants, representing nonbranched fatty acids (C~32~--C~34~) with a γ-lactone moiety.^[@ref1]^ In most cases, acetogenin molecules contain additional hydroxy, keto, epoxy, tetrahydrofuran, or tetrahydropyran groups as well as double and triple bonds. The enhanced interest in this class of compounds is due to a wide range of biological activities they exhibit such as antibacterial, immunosuppressive, antimalarial, anticancer, and antiprotozoal activities.^[@ref2]^ Moreover, it has been shown that acetogenins, as well as compounds containing a 2,5-bis(hydroxymethyl)tetrahydrofuran moiety, are capable of exerting a cytotoxic effect on multidrug-resistant tumors due to inhibition of the ATP synthesis and are among the most active of currently known mitochondrial complex I inhibitors.^[@ref3]^ In addition, acetogenins can interact with DNA polymerases and topoisomerases, thus affecting the synthesis of deoxyribonucleic acids in the cell.^[@ref4]^ The possibility of affecting the regulation of cell cycle by relatively low concentrations of these substances, together with pronounced antitumor action and a relatively beneficial effect on healthy cells, makes this class of compounds promising for the development of new highly effective antitumor agents. Since plants produce exceptionally low (nanogram) quantities of acetogenins, a chemical synthesis is the only option for obtaining these compounds for practical use. It is important to ensure high stereoselectivity of the resulting compounds since the activity of these bioregulators is crucially affected by the geometry of the double bonds and asymmetric centers present in molecules.^[@ref5]^

Currently, quite a number of examples of synthesizing of structurally diverse acetogenins and their analogues have been reported in the literature; in the vast majority of cases, these are representatives of the acetogenin family containing one to three furan moieties in the molecule, with the major synthetic strategy being successive assembly of the molecule from small blocks by known C--C bond formation protocols.^[@ref6]^ Despite that an effective approach to cascade cyclization of the above-described unsaturated compounds has now been developed; at the same time, it has been shown that the crucial factor dictating the stereoselective formation of tetrahydrofurans and hydroxyl groups is a strict stereoconfiguration of substituents at the double bonds.

The Ru-catalyzed oxidative cyclization of 1*Z*,5*Z*-dienes yields only *anti*,*anti*-stereoisomers of 2,5-bis(hydroxymethyl)tetrahydrofurans, which exhibit the highest antitumor and antibacterial activities.^[@ref7]^

Development of the strategy for the total synthesis of acetogenins containing tetrahydrofuran moieties via the oxidative cyclization of the appropriate bis-methylene-separated di- and polyenes is mainly hampered, in our opinion, by the lack of an efficient synthetic approach to the latter. A survey of literature indicates that methods used, most often, to generate the 1*Z*,5*Z*-diene moiety are based on the Wittig reaction, olefin metathesis, and stereoselective catalytic hydrogenation of acetylenes.^[@ref8]^ The task becomes more challenging if the synthesis implies the formation of compounds containing three or more *Z*-double bonds.

The previously developed Ti-catalyzed homo- and cross-cyclomagnesiation of 1,2-dienes, which leads to strictly stereoselective formation of metal--carbon and carbon--carbon bonds, could be successfully utilized as a convenient and versatile tool in the stereoselective synthesis of various 1*Z*,5*Z*-diene derivatives ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref9]^

![Ti-Catalyzed Homo- and Cross-Cyclomagnesiation of 1,2-Dienes](ao9b01951_0005){#sch1}

The results reported in the papers mentioned above^[@ref9]^ can be used for the synthesis of a broad range of natural biologically active compounds, higher 5*Z*,9*Z*-dienoic acids, insect pheromones, lembehynes, unique macrocarbocycles, and also acetogenins.^[@ref4],[@ref10]^

In particular, previously, we developed an original five-step synthesis of a natural acetogenin, muricadienin **1**, a bioprecursor of *cis*-solamin **2** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), giving the product in ∼60% yield. The synthesis involved cross-cyclomagnesiation of functionally substituted allenes with EtMgBr in the presence of Mg metal (halogen ion acceptor) and catalyzed by Ti complexes as the key step. In addition, we previously found that muricadienin exhibits inhibitory activity in vitro against key cell cycle enzymes human topoisomerases I and IIα and has high cytotoxicity against human embryonic kidney cells HEK293 (IC~50~ = 0.39 μM).^[@ref4]^

![Structures of muricadienin, chatenaytrienin-l and 4,*cis*-solamin and membranacin.](ao9b01951_0007){#fig1}

Considering the practical value of research aimed at the search for new preparative approaches for the syntheses of natural biologically active compounds with a *Z*-polyunsaturated hydrocarbon chain and also to study the applicability of reactions we developed for the preparation of more structurally sophisticated acetogenins, here, we intended to synthesize chatenaytrienin-1 **3** using the Ti-catalyzed cross-cyclomagnesiation of 1,2-dienes as the key step.

Chatenaytrienin-l **3**, which was isolated in 1998 by Gleye and co-workers from *Annona muricata*, is a natural triene bioprecursor of Annonaceous acetogenin, membranacin **5**, containing a bis-THF moiety ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref11]^

When our study was started, only a single example of synthesizing a structurally similar homologue of compound **3**, chatenaytrienin-4 **4**, was available from the literature. Compound **4** was prepared in 15 steps in an overall yield of 6%.^[@ref12]^

Results and Discussion {#sec2}
======================

Initially, we carried out the retrosynthetic analysis of the chatenaytrienin-l **3**, which implied the successive synthesis of (11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trienoic acid **6** by means of catalytic cross-cyclomagnesiation followed by the construction of α-substituted butenolide, with the Fries rearrangement being the final step of the synthesis of the target triene ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

![Retrosynthetic Analysis of Chatenaytrienin-1](ao9b01951_0004){#sch2}

The initial monomer needed for the preparation of *Z*,*Z*,*Z*-trienoic acid **6**, (6*Z*)-heptadec-1,2,6-triene **10**, was synthesized in several steps using the alkylation of commercially available dodec-1-yne **8** with ethylene oxide ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).^[@ref13]^ The subsequent selective hydrogenation of alcohol **12** was carried out in the presence of Brown's catalyst P2--Ni and afforded unsaturated alcohol **9** with *Z*-configuration of the double bond in ∼98% yield.^[@ref14]^ Ethynylation of compound **13**, obtained by bromination of alcohol **9** with LiBr,^[@ref15]^ on treatment with lithium acetylenide yielded (5*Z*)-hexadec-5-en-1-yne **14** in a quantitative yield.^[@ref16]^ Allene **10** was obtained from alkyne **14** by the Crabbé reaction that involves refluxing with paraformaldehyde, dicyclohexylamine, and copper iodide.^[@ref17]^

![Synthesis of (6*Z*)-Heptadeca-1,2,6-triene](ao9b01951_0003){#sch3}

According to the developed synthetic strategy, (11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trienoic acid **6** was prepared by the cross-cyclomagnesiation of (6*Z*)-heptadeca-1,2,6-triene **10** and trideca-11,12-dien-1-ol tetrahydropyran acetal **11** with EtMgBr in the presence of Mg metal and the Cp~2~TiCl~2~ catalyst (10 mol %) at room temperature ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). The reaction proceeded via the intermediate magnesacyclopentane **15**, which was hydrolyzed to give (11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trien-1-ol tetrahydropyran acetal **16** in 85% yield. The subsequent oxidation of tetrahydropyran acetal **16** with the Jones reagent gave the desired *Z*,*Z*,*Z*-trienoic acid **6**.

![Titanium-Catalyzed Cross-Cyclomagnesiation of Allenes](ao9b01951_0002){#sch4}

All that remains for the synthesis of chatenaytrienin-l **3** was the formation of the terminal butenolide moiety, which was effected by a method that proved useful,^[@ref18]^ based on the Fries rearrangement catalyzed by DMAP ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}). Indeed, O-acylation of cyclic β-keto ether **7**, which was obtained from (*S*)-ethyl lactate by a reported two-step procedure,^[@ref19]^ with acid **6** followed by the DMAP-initiated rearrangement afforded triene **17**, which was then undergo reduction by NaBH~3~CN in acetic acid to produce α-alkylated butenolide **18** in a yield of more than 97%.

![Fries Rearrangement: Introduction of the Terminal α-Substituted Butenolide](ao9b01951_0001){#sch5}

The hydroxyl group in the C3-position of butenolide was eliminated by successive synthesis of triflate **19** and its reduction with Bu~3~SnH catalyzed by Pd~2~(dba)~3~; this gave the target chatenaytrienin-l **3** in ∼91% yield.^[@cit8k]^

Conclusions {#sec3}
===========

Thus, we have achieved the first stereoselective 10 step synthesis of chatenaytrienin-l using Ti-catalyzed cross-cyclomagnesiation of aliphatic and oxygenated 1,2-dienes with the Grignard reagent. This study demonstrates the enormous synthetic potential of the proposed method as a convenient tool for stereoselective preparation of 1*Z*,5*Z*-diene systems. Currently, our efforts are focused on the synthesis of a number of natural homologues of chatenaytrienin-l to obtain larger amounts of these products and conduct extensive studies of their antitumor, antibacterial, and antiparasitic activities.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

1-Dodecyne, lithium acetylide, ethylene diamine complex, nickel (II) acetate tetrahydrate (Ni(OAc)~2~·4H~2~O), dicyclohexylamine, copper (I) iodide (CuI), bis(cyclopentadienyl)titanium (IV) dichloride (Cp~2~TiCl~2~), 4-dimethylaminopyridine (DMAP), *N*,*N*′-dicyclohexylcarbodiimide (DCC), sodium cyanoborohydride (NaBH~3~CN), trifluoromethanesulfonic anhydride (Tf~2~O), and tris(dibenzylideneacetone)dipalladium(0) (Pd~2~(dba)~3~) were obtained from Sigma-Aldrich and Acros organics. All reactions were carried out under an argon atmosphere. ^1^H and ^13^C NMR spectra were obtained using a Bruker Ascend 500 spectrometer in CDCl~3~ operating at 500 MHz for ^1^H and 125 MHz for ^13^C and a Bruker AVANCE 400 spectrometer in CDCl~3~ operating at 400 MHz for ^1^H and 100 MHz for ^13^C. IR spectra were recorded on a Bruker VERTEX 70V using KBr discs over the range of 400--4000 cm^--1^. Mass spectra of MALDI TOF/TOF positive ions (matrix of sinapic acid) are recorded on a mass spectrometer Bruker Autoflex III Smartbeam. Elemental analyses were measured on a 1106 Carlo Erba apparatus. Individuality and purity of the synthesized compounds were controlled using TLC on Sorbfil plates; anisic aldehyde in acetic acid was used as a developer. Column chromatography was carried out on Acrus silica gel (0.060--0.200 mM).

### Cross-Cyclomagnesiation of (6*Z*)-Heptadeca-1,2,6-triene (**10**) and 2-(Trideca-11,12-dien-1-yloxy)tetrahydro-2*H*-pyran (**11**) by EtMgBr in the Presence of Mg Metal and Cp~2~TiCl~2~ Catalyst (General Procedure) {#sec4.1.1}

Diethyl ether (50 mL), (6*Z*)-heptadeca-1,2,6-triene **10** (2.3 g, 10.0 mmol), 2-(trideca-11,12-dien-1-yloxy)tetrahydro-2*H*-pyran **11** (2.3 g, 8.4 mmol), EtMgBr (66.8 mL, 100.2 mmol) (as 1.5 M solution in Et~2~O), Mg powder (3.0 g, 125.8 mmol), and Cp~2~TiCl~2~ (0.4 g, 1.8 mmol) were charged into a glass reactor with stirring under argon (∼0 °C). The reaction mixture was heated to 20--22 °C and stirred for 24 h. The reaction mixture was treated with a 5% solution of NH~4~Cl in H~2~O (30 mL) and extracted with diethyl ether (2 × 100 mL). The combined organic phases were dried over MgSO~4~ and filtrated. Then, the solvent was removed under reduced pressure. Silica gel column chromatography (hexane/EtOAc = 35:1) of the residue gave compound **16**.

### 2-\[(11*Z*,15*Z*,19*Z*)-Triaconta-11,15,19-trien-1-yloxy\]tetrahydro-2*H*-pyran (**16**) {#sec4.1.2}

Yield 8.1 g (85%), pale yellow oily liquid. ^1^H NMR (500 MHz, CDCl~3~, δ): 5.45--5.35 (m, 6H), 4.59 (m, 1H), 3.89 (m, 1H), 3.75 (m, 1H), 3.52 (m, 1H), 3.40 (m, 1H), 2.10 (m, 6H), 2.04 (m, 6H), 1.85 (m, 1H), 1.73 (m, 1H), 1.63--1.52 (m, 6H), 1.40--1.25 (m, 30H), 0.90 (t, *J* = 6.5 Hz, 3H). ^13^C NMR (125 MHz, CDCl~3~, δ): 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 98.8, 67.7, 62.3, 31.9, 30.8, 29.8--29.3 (signals of 13C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 26.3, 25.5, 22.7, 19.7, 14.1. IR (film): 3008, 2956, 2924, 1644, 1612, 1466, 1404, 1302, 1261, 996, 902, 841, 783, 721, 655, 611 cm^--1^. Anal. Calcd for C~35~H~64~O~2~: C, 81.33; H, 12.48. Found: C, 81.19; H, 12.46. MALDI TOF: *m*/*z* 539.538 (\[M + Na\]^+^, calcd 539.480).

### Oxidation of 2-\[(11*Z*,15*Z*,19*Z*)-Triaconta-11,15,19-trien-1-yloxy\]tetrahydro-2*H*-pyran **16** with Jones Reagent {#sec4.1.3}

To a solution of 2-\[(11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trien-1-yloxy\]tetrahydro-2*H*-pyran **16** (8.0 g, 15.3 mmol) in acetone (100 mL) and CH~2~Cl~2~ (25 mL) at room temperature, Jones reagent (18.7 mL) was added dropwise. The reaction mixture was stirred at room temperature for 1 h, quenched with water (50 mL), and concentrated to remove the excess of acetone and CH~2~Cl~2~. Then, the aqueous layer was extracted with diethyl ether (3 × 100 mL). The organic layer was dried over MgSO~4~ and concentrated in vacuo. The residue was purified by column chromatography using hexane/EtOAc = 30:1 as the elution solvent to afford (11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trienoic acid **6**.

### (11*Z*,15*Z*,19*Z*)-Triaconta-11,15,19-trienoic Acid (**6**) {#sec4.1.4}

Yield 5.3 g (78%), colorless oil. ^1^H NMR (500 MHz, CDCl~3~, δ): 5.45--5.35 (m, 6H), 2.36 (t, *J* = 7.5 Hz, 2H), 2.11 (m, 6H), 2.05 (m, 6H), 1.65 (m, 2H), 1.40--1.25 (m, 28H), 0.90 (t, *J* = 6.4 Hz, 3H). ^13^C NMR (125 MHz, CDCl~3~, δ): 180.1, 130.4, 130.3, 129.6 (signals of 2C), 129.1 (signals of 2C), 34.1, 31.9, 29.8--29.1 (signals of 12C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 24.7, 22.7, 14.1; IR (film): 2926, 2851, 1712, 1466, 1374, 1309, 1283, 1260, 1230, 1206, 1183, 965, 935, 723, 722 cm^--1^. Anal. Calcd for C~30~H~54~O~2~: C, 80.65; H, 12.18. Found: C, 80.49; H, 12.16. MALDI TOF: *m*/*z* 469.508 (\[M + Na\]^+^, calcd 469.402), 485.398 (\[M + K\]^+^, calcd 485.376).

### Synthesis of (5*S*)-4-Hydroxy-5-methyl-3-\[(11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trien-1-yl\]furan-2(5*H*)-one (**18**) {#sec4.1.5}

DIPEA (2.3 mL, 13.3 mmol) was added to a suspension of butenolide **7** (1.5 g, 13.3 mmol), fatty acid **6** (5.2 g, 11.7 mmol), 4-DMAP (0.4 g, 3.3 mmol), and DCC (2.7 g, 13.3 mmol) in DCM (50 mL) at 0 °C. The reaction mixture was stirred overnight with warming to room temperature. The yellow solution was filtered, and the solid was washed with diethyl ether. The filtrate was concentrated, and the residue was dissolved in ethyl acetate. The organic phase was washed with a solution of 1 N HCl and brine, dried over MgSO~4~, filtrated, and concentrated under reduced pressure. To remove residual urea derivative, the mixture was dissolved in diethyl ether, filtrated, and concentrated in vacuo to yield a brownish solid that was directly used in the subsequent reduction step. To this end, the crude product was dissolved in acetic acid (30 mL), and NaBH~3~CN (5.3 g, 23.4 mmol) was slowly added at 10 °C. The reaction mixture was stirred overnight with warming to room temperature and then poured into a solution of 1 N HCl (10 mL). The aqueous layer was extracted with ethyl acetate (3 × 50 mL). The combined organic phases were washed with H~2~O and brine, dried over MgSO~4~, filtrated, and concentrated in vacuo (3 × codestillation with toluene to remove acetic acid). The title compound **18** was obtained in analytically pure product.

### (5*S*)-4-Hydroxy-5-methyl-3-\[(11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trien-1-yl\]furan-2(5*H*)-one (**18**) {#sec4.1.6}

Yield 5.6 g (90%), colorless waxy solid. \[α\]~D~^21^ + 1.0 (*c* 0.71, CHCl~3~). ^1^H NMR (500 MHz, CDCl~3~, δ): 5.46--5.37 (m, 6H), 4.84 (q, *J* = 6.5 Hz, 1H), 2.22 (t, *J* = 7.5 Hz, 2H), 2.10 (m, 6H), 2.05 (m, 6H), 1.52 (d, *J* = 6.5 Hz, 3H), 1.48 (m, 2H), 1.40--1.25 (m, 30H), 0.89 (t, *J* = 6.5 Hz, 3H). ^13^C NMR (125 MHz, CDCl~3~, [δ]{.ul}): 177.7, 177.4, 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 100.9, 75.3, 31.9, 29.7--29.4 (signals of 13C), 28.1, 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 22.7, 21.1, 17.8, 14.1. IR (film): 3005, 2924, 2853, 1751, 1730, 1654, 1457, 1376, 1313, 1267, 1249, 1180, 1142, 1081, 1078, 777, 722 cm^--1^. Anal. Calcd for C~35~H~60~O~3~: C, 79.49; H, 11.44 Found: C, 79.39; H, 11.41. MALDI TOF: *m*/*z* 551.518 (\[M + Na\]^+^, calcd 551.444), 567.481 (\[M + K\]^+^, calcd 567.418).

### Synthesis of (2*S*)-2-Methyl-5-oxo-4-\[(11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trien-1-yl\]-2,5-dihydrofuran-3-yl Trifluoromethanesulfonate (**19**) {#sec4.1.7}

DIPEA (2.5 mL, 14.1 mmol) was added to a stirred solution of compound **18** (5.0 g, 9.4 mmol) in DCM (100 mL) at room temperature. The solution was cooled to −78 °C and Tf~2~O (3.1 g, 1.9 mL, 10.9 mmol) was slowly added. The mixture was stirred at −78 °C for 2 h. After complete conversion, DCM (20 mL) was added, and the reaction mixture was extracted with a solution of 1 N HCl (100 mL). The combined organic phases were washed with H~2~O, brine, dried over MgSO~4~, and filtrated. The solvents were removed under reduced pressure. Silica gel column chromatography (hexane/EtOAc = 30:1) of the residue gave triflate **19**.

### (2*S*)-2-Methyl-5-oxo-4-\[(11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trien-1-yl\]-2,5-dihydrofuran-3-yl Trifluoromethanesulfonate (**19**) {#sec4.1.8}

Yield 5.6 g (91%), pale yellow oil. \[α\]~D~^21^ + 17.0 (*c* 0.71, CHCl~3~). ^1^H NMR (500 MHz, CDCl~3~, δ): 5.46--5.37 (m, 6H), 5.13 (q, *J* = 6.8 Hz, 1H), 2.33 (t, *J* = 7.2 Hz, 2H), 2.11 (m, 6H), 2.04 (m, 6H), 1.61 (m, 2H), 1.56 (d, *J* = 6.8 Hz, 3H), 1.40--1.23 (m, 30H), 0.90 (t, *J* = 6.4 Hz, 3H). ^13^C NMR (125 MHz, CDCl~3~, δ): 169.1, 163.4, 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 121.9, 118.4 (*J* = 319 Hz), 74.4, 31.9, 29.7--29.1 (signals of 13C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 26.7, 22.7 (signals of 2C), 17.7, 14.1. IR (film): 3005, 2924, 2853, 1751, 1730, 1654, 1457, 1376, 1313, 1267, 1249, 1180, 1142, 1081, 1078, 777, 722 cm^--1^. Anal. Calcd for C~36~H~59~F~3~O~5~S: C, 65.42; H, 9.00 Found: C, 65.36; H, 8.97. MALDI TOF: *m*/*z* 683.418 (\[M + Na\]^+^, calcd 683.404).

### Synthesis of (5*S*)-5-Methyl-3-\[(11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trien-1-yl\]furan-2(5*H*)-one (Chatenaytrienin-l **3**) {#sec4.1.9}

Pd~2~(dba)~3~ (13.7 mg, 0.015 mmol, 1.5 mol %) and PPh~3~ (39.3 mg, 0.15 mmol, 15.0 mol %) were dissolved in dry THF (10 mL). After stirring for 5 min at room temperature, triflate **19** (0.7 g, 1.0 mmol) and Bu~3~SnH (0.8 mL, 3.0 mmol) were added to the orange solution. The mixture was heated to 50 °C and stirred at this temperature for 5 h. After complete conversion of the starting material, the reaction was cooled to room temperature, diluted with H~2~O (10 mL), and extracted with diethyl ether (3 × 30 mL). The combined organic phases were dried over MgSO~4~ and filtrated. Then, the solvents were removed under reduced pressure. Silica gel column chromatography (hexane/EtOAc = 20:1) of the residue gave chatenaytrienin-l **3**.

### (5*S*)-5-Methyl-3-\[(11*Z*,15*Z*,19*Z*)-triaconta-11,15,19-trien-1-yl\]furan-2(5*H*)-one (**3**) {#sec4.1.10}

Yield 0.4 g (88%), colorless waxy solid. \[α\]~D~^21^ + 12.8 (*c* 0.64, CHCl~3~). ^1^H NMR (500 MHz, CDCl~3~, δ): 6.99 (d, ^3^*J* = 1.0 Hz, 1H), 5.45--5.33 (m, 6H), 5.00 (qd, ^3^*J* = 6.5, ^3^*J* = 1.5 Hz, 1H), 2.28 (t, *J* = 7.5 Hz, 2H), 2.09 (m, 6H), 2.04 (m, 6H), 1.56 (m, 2H), 1.42 (d, *J* = 6.5 Hz, 3H), 1.38--1.25 (m, 30H), 0.89 (t, *J* = 6.5 Hz, 3H). ^13^C NMR (125 MHz, CDCl~3~, δ): 173.9, 148.8, 134.3, 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 77.4, 31.9, 29.8--29.2 (signals of 13C), 27.5 (signals of 3C), 27.4 (signals of 3C), 27.3, 25.2, 22.7, 19.2, 14.1. IR (film): 2924, 2853, 1759, 1654, 1619, 1458, 1375, 1318, 1261, 1198, 1075, 1027, 968, 875, 722 cm^--1^; Anal. Calcd for C~35~H~60~O~2~: C, 81.97; H, 11.79 Found: C, 81.81; H, 11.76. MALDI TOF: *m*/*z* 535.521 (\[M + Na\]^+^, calcd 535.449), 551.469 (\[M + K\]^+^, calcd 551.423).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.9b01951](http://pubs.acs.org/doi/abs/10.1021/acsomega.9b01951).Methods of synthesis and characterization data of the products **3**, **6**, **9**--**14**, **18**, and **19** as well as copies of ^1^H and ^13^C NMR spectra of final products ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01951/suppl_file/ao9b01951_si_001.pdf))
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